
The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.
Dr Ward is a psychiatrist, director of neuromodulation research, director of the Vanderbilt Psychiatry Residency Research Track, and an assistant professor of psychiatry and behavioral sciences at Vanderbilt University Medical Center in Nashville, Tennessee.
The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.
Research presented at the ACNP 2023 Annual Meeting shows that neuromodulation therapy cTBS could be a viable schizophrenia-specific intervention for nicotine use.
Published: December 5th 2023 | Updated:
Published: March 27th 2025 | Updated: